Urine keratin, II-type cytoskeleton 1 and application of polypeptide fragment thereof in allergic diseases

A technology of allergic diseases and cytoskeleton, which is applied in disease diagnosis, material inspection products, measuring devices, etc., can solve the problems of poor patient compliance, increased systemic allergic symptoms, and susceptibility to drugs

Inactive Publication Date: 2021-07-09
BEIJING SHIJITAN HOSPITAL CAPITAL MEDICAL UNIVERSTY
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, clinical auxiliary examinations for allergic diseases mainly include skin prick test (SPT) and serum sIgE detection, etc. However, patients with SPT test have poor compliance, are easily affected by drugs, and can increase the occurrence of systemic allergic symptoms risk, not suitable for severe allergies and children and elderly groups

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Urine keratin, II-type cytoskeleton 1 and application of polypeptide fragment thereof in allergic diseases
  • Urine keratin, II-type cytoskeleton 1 and application of polypeptide fragment thereof in allergic diseases
  • Urine keratin, II-type cytoskeleton 1 and application of polypeptide fragment thereof in allergic diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1 Urine Specimen Collection and Processing

[0023] A total of 60 outpatients diagnosed with allergic diseases in Beijing Shijitan Hospital Affiliated to Capital Medical University were collected as the allergic disease (allergic disease) group, aged 23-58 years. A total of 60 healthy persons who underwent physical examination at the Physical Examination Center of Beijing Shijitan Hospital Affiliated to Capital Medical University were collected as the control group. After the urine was collected, it was centrifuged at 400×g for 5 minutes, the supernatant was taken, aliquoted, and frozen at -80°C. A comparison of the clinical characteristics of these study subjects is shown in Table 1.

[0024] Table 1 Comparison of general clinical data between the allergic disease (allergic disease) group and the control group.

[0025]

Embodiment 2

[0026] Example 2 Magnetic bead purification and screening of urine peptides

[0027]Weak cation-exchange magnetic beads were used to enrich the peptides in urine, and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) was used to analyze the peptide spectrum in urine. Mix 1 μl of eluate with 10 μl of matrix (0.3 % α-cyano-4-hydroxycinnamic acid, HCCA), take 1 μl to spot on the Anchorchip target plate, and dry at room temperature. The specimens were ionized by irradiation with a nitrogen laser, and calibrated before the specimens were subjected to further mass spectrometric analysis. After calibrating the instrument with a standard, test the sample, collect data in the range of 1-10kDa, and obtain a mass spectrum composed of protein peaks with different mass-to-charge ratios. For each MALDI target, a total of 400 laser shots were made. 8 different positions of each target point were irradiated 50 times, and the average value represe...

Embodiment 3

[0028] Example 3 Identification and Analysis of Differential Peptides

[0029] Take 20 ul from the sample tube for LC-MS / MS analysis. EASY-nLC1000 HPLC system was used for separation. Liquid phase A was 0.1% formic acid in acetonitrile (2% acetonitrile), and liquid phase B was 0.1% formic acid in acetonitrile (98% acetonitrile). The chromatographic spray needle is PN: FS360-20-10-N-20-C12. Samples were separated by capillary high-performance liquid chromatography and analyzed by a Q-Exactive mass spectrometer (Thermo). The ion source voltage is 3.5kv, the analysis time is 120min, and the precursor ion scanning range is 300-2000m / z. Mass-to-charge ratios of peptides and peptide fragments were collected as follows: 20 fragments were collected after each full scan (MS2scan, HCD). At M / Z200, MS1 has a resolution of 70,000 and MS2 has a resolution of 17,500. The data analysis software Peaks8.5 (Bioinformatics Solutions Inc.) was used for retrieval. The search database was ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of a urine keratin, type II cytoskeletal 1 (Keratin, type II cytoskeletal 1) protein and a polypeptide fragment thereof, and particularly relates to an application of the urine keratin, type II cytoskeletal 1 and the polypeptide fragment thereof in preparation of a preparation for detecting allergic diseases. The allergic diseases are also known as allergic diseases, and the typical allergic diseases (allergic diseases) comprise allergic rhinitis, bronchial asthma, allergic dermatitis, eczema, allergic conjunctivitis, allergic shock and the like, and are collectively known as allergic diseases below. Researches prove that compared with a healthy human group (normal control), the expression of the urine keratin, II type cytoskeleton 1 and the polypeptide fragment thereof in an allergic disease patient group is improved, and the urine keratin, II type cytoskeleton 1 and the polypeptide fragment thereof can be used for auxiliary diagnosis of allergic disease patients. The advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of the urine sample are exerted, and the urine keratin, II-type cytoskeleton 1 and the polypeptide fragments thereof are detected by utilizing the urine sample.

Description

technical field [0001] The present invention relates to the new application of urinary keratin, type II cytoskeleton 1 and its polypeptide fragments, in particular to the application of urinary keratin, type II cytoskeleton 1 and its polypeptide fragments in monitoring allergic diseases. Background technique [0002] Allergic diseases are also known as allergic diseases. Typical allergic diseases include allergic rhinitis, bronchial asthma, allergic dermatitis, eczema, allergic conjunctivitis and anaphylactic shock. According to the statistics of the World Health Organization, the number of allergic people in the world is huge, and about one-third of the people have suffered from allergic diseases. In recent years, due to the rapid changes in people's lifestyles, the significant increase in the degree of industrialization, and the obvious aggravation of air pollution, the incidence of allergic diseases has increased year by year. [0003] At present, clinical auxiliary exam...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCG01N33/6893G01N2800/24G01N2333/4742G01N2333/47
Inventor 张曼刘娜
Owner BEIJING SHIJITAN HOSPITAL CAPITAL MEDICAL UNIVERSTY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap